Matthew Bell

Postdoctoral Fellow @CHUVLausanne | @Kyttaro_Therapy lab @stjudegraduate PhD | interested in synthetic biology and cancer immunotherapy

[Matthew Bell @Matthew_R_Bell]

I'm pleased to announce that my Ph.D. project was finally published! We show that synthetic cytokine receptors improve CAR T cells against solid tumors

https://t.co/Rf4jHHUCaV

[NASA's Kennedy Space Center @NASAKennedy]

The planet can spell your name – literally. 🔤🌍

This Earth Day, see your name written in landscapes captured by Landsat: https://t.co/kcP12dhsI2

[Max Mamonkin @MaxMamonkin]

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team @CAGTHouston and beyond
https://t.co/v2tnnnVpUv

[Matthew Bell @Matthew_R_Bell]

@Larsen_in_Lab Fantastic to see and very well deserved!

[Matthew Bell @Matthew_R_Bell]

@BeltraJc @parkerici @EJohnWherry Fantastic work! Great to see this mechanistic explanation that supports the utility of STAT5 activators in T cell therapies

[Matthew Bell @Matthew_R_Bell]

If you want to learn more about our work on engineered cytokine receptors for CAR T cell therapy, check out the "Behind the Paper" on our recent @natBME article

https://t.co/5NqWq0iCD1

[Matthew Bell @Matthew_R_Bell]

I'd like to especially thank @Kyttaro_Therapy for his unyielding support, @StJudeResearch and @stjudegraduate, the staff at @natBME, and the reviewers whose critical peer review made a substantive improvement to the manuscript

[Matthew Bell @Matthew_R_Bell]

This project was the result of more than a little stubborn determination and the support of incredible co-authors and mentors.

[Matthew Bell @Matthew_R_Bell]

I'm pleased to announce that my Ph.D. project was finally published! We show that synthetic cytokine receptors improve CAR T cells against solid tumors

https://t.co/Rf4jHHUCaV

[Matthew Bell @Matthew_R_Bell]

Big news coming soon 🍾

[PhD_Genie @PhD_Genie]

When your paper gets published!

[Alex Beckett, PhD @AlexBeckettPhD]

Thesis defense completed ✅

[Veera Rajagopal  @doctorveera]

A mind-blowing paper has come out today in @Nature

In 2016, JC Venter Institute scientists trimmed a bacterial genome to its barest minimum required for life to synthesize what they called a "minimal genome" (https://t.co/Rk8oZJ0bUj).

Today, a group of scientists from Indiana University reports how that minimal genome evolved over 2000 generations in comparison to the non-minimal genome.

The authors found that even when you reduce a bacterial genome to its absolute minimum where every nucleotide matters, the genome undergoes mutational events generation after generation as much as the non-minimal genome. One simply cannot stop the evolution.

Just over 300 days of evolution (equivalent to 40,000 years in humans) the minimal cell has gained everything it lacked in fitness on day one in comparison to the non-minimal cell.

When comparing the evolved traits between the minimal and non-minimal cells, the scientists found something striking. The evolutionary process increased the cell size of non-minimal cells but not that of the minimal cell. But that is not the striking part.

The scientists were able to identify the key mutation that resulted in cell size evolution. And it turned out that the mutation that helped the non-minimal cells to grow bigger is the same that helped the minimal cells to stay smaller. Growing bigger had a survival advantage for non-minimal cells and not growing bigger had a survival advantage for minimal cells. So, the mutation had a context-dependent effect. This just demonstrates that the evolutionary effects on traits have no absolute direction. All that matter is what is beneficial for the organism's survival.

The conclusion of the paper is metaphorically a quote from the Jurassic Park movie:

“Listen, if there’s one thing the history of evolution has taught us is that life will not be contained. Life breaks free. It expands to new territories, and it crashes through barriers painfully, maybe even dangerously, but . . . life finds a way". (https://t.co/UlxRlb86CT)

https://t.co/zA9OAqSoAu

[Jesus Corria-Osorio @CorriaJesus]

Delighted to share our more recent work about IL-2-related, non canonical , synthetic CD8 T cell states, now published in ⁦@NatImmunol⁩ . Huge thanks to ⁦@CoukosGeorge⁩ , ⁦@carmonation⁩ , ⁦@IrvingMelita⁩ and the whole team. https://t.co/Axz9u1HWys

[Matthew Bell @Matthew_R_Bell]

@the_transit_guy Yes! So happy to have recently moved here from a car centric US city

[Matthew Bell @Matthew_R_Bell]

Impactful findings from @itsalexbeckett @stjudegraduate. This has implications for auto and allo CAR T therapy and also CD47 blockade and autoimmunity

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: CD47 expression is critical for CAR T-cell survival in vivo https://t.co/ZZ8as34Uj7 @itsalexbeckett

[John Connolly @John_E_Connolly]

Interesting paper highlighting the role of CD47 in CAR T function. @StJudeResearch

[Lindsay Schwarz 🌧 @lindsayschwarz]

presenting the first Schwarz lab preprint🎉: A Novel Single Vector Intersectional AAV Strategy for Interrogating Cellular Diversity and Brain Function https://t.co/v2vurMf9dH (1/n)

[Matthew Bell @Matthew_R_Bell]

Synapse tuning enhances CARs. Most impressive is tumor clearance with a single dose of CAR NK cells (No cytokines or other co-treatment) and functional persistance of NK cells to day 120 to reject tumor rechallenge.
Great work @PeterChockley!

https://t.co/AVgy46ADB8

[St. Jude Research @StJudeResearch]

“We've come up with a way to more efficiently and effectively bind and target cancer cells,” @PeterChockley says. Discover how his ‘molecular anchor’ improved chimeric antigen receptors against multiple cancer types in @NatureBiotech. https://t.co/JycmBMD0CL #immunotherapy

[Daniel Connolly 〽️ @DanielConnolly]

We're heading into a tense night with the release of the video of #TyreeNichols fatal encounter with Memphis police. I covered similar deaths in Memphis for years. Here's a thread on why this case gained so much attention - and why it's _different_ from other cases. 1/18